Manuel García-Ruiz, Pablo Mayo Rodríguez, Luca Palliotti, Clara Lastras, María Romeral-Jiménez, Irene García Morales, Cándido Pardo Rey, Marc Rodrigo-Gisbert, Daniel Campos-Fernández, Estevo Santamarina, Beatriz Parejo Carbonell
PURPOSE: There is insufficient evidence on the management of refractory status epilepticus (RSE) and super-RSE (SRSE). Ketamine is a N-methyl-d-aspartate receptor antagonist in the treatment of these entities. Our objectives were to study the effectiveness and safety of ketamine in the treatment of adult patients with RSE and SRSE, to determine the factors that can influence the response to ketamine, and to explore its use in patients without mechanical ventilation. METHODS: Adult patients who had received intravenous ketamine for the treatment of RSE or SRSE at Hospital Universitario Clínico San Carlos (Madrid, Spain) or Hospital Universitari Vall d'Hebron (Barcelona, Spain) from 2017 to 2023 were retrospectively analysed...
January 22, 2024: Seizure: the Journal of the British Epilepsy Association